← Leaderboard
NVO
Ticker
NVO
Congressional Trades
46
by 10 members
Buys
23
50%
Sells
22
48%
Total Volume
$1.1M
midpoint
Unique Traders
10
members
Party Breakdown
Democrats5 · 11%
Republicans41 · 89%
Party Trading Divergence
Democrat vs. Republican buy / sell pressure by monthALIGNEDBar length = total trades. Color = net sentiment — green = net buying, red = net selling. Months with no activity hidden.
Democrat ←
Month
→ Republican
—
Jan '24
0▲1▼
0▲1▼
Feb '24
—
—
Apr '24
3▲
—
May '24
3▲
0▲1▼
Jul '24
—
—
Aug '24
1▲1▼
—
Sep '24
0▲1▼
1▲
Oct '24
—
—
Nov '24
0▲2▼
—
Mar '25
2▲1▼
—
May '25
1▲3▼
—
Jun '25
2▲2▼
—
Jul '25
0▲3▼
—
Aug '25
4▲2▼
—
Sep '25
2▲
—
Oct '25
2▲4▼
1▲
Feb '26
—
1▲
Mar '26
—
Democrats3▲2▼Net buyers
vs
Republicans20▲20▼Neutral
Net buyingNet selling⚡ Party split
💼 Lobbying Filings
all →- 2026-04-22$10KNOVO NORDISK INC.
- 2026-04-20$1.3MNOVO NORDISK INC.Obesity, Treat and Reduce Obesity Act, Insulin Pricing/affordability, IRA implementation and drug pricing legislation, supply chain, 340B, Intellectual Property/patent protection, S. 150 - the Affordable Prescriptions for Patients Act, Protect 340B Act, PBM Reform Act, General Compounding Labor-HHS Appropriations Bill, Military Construction, Treat and Reduce Obesity Act, General Compounding, FDA Agricultural Appropriations bill Obesity, Treat and Reduce Obesity Act, IRA implementation, General engagement around drug pricing S. 150, Affordable Prescriptions for Patients Act, Patent Protection, General IP Issues, General Compounding International and corporate tax issues Tariffs and trade policy
- 2026-04-20$80KNOVO NORDISK INC.Issues related to compounding and counterfeit drugs. Issues related to drug pricing and implementation of the Inflation Reduction Act. H.R. 1492, the Ensuring Pathways to Innovative Cures Act. Issues related to coverage of anti-obesity medications. Issues related to pharmacy benefit management reforms. Issues related to Most Favored Nation drug pricing. Monitored issues related to the implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes and foreign-based multinationals. Monitor OECD negotiations on the Pillar II global minimum tax. Issues related to tariffs. Issues related to importation of counterfeit drugs.
- 2026-04-20$80KNOVO NORDISK INC.Issues related to Medicare coverage of Anti-Obesity Medicines. Issues related to pharmaceutical supply chain transparency and integrity. Issues related to compounding and counterfeit medicines.
- 2026-04-20$60KNOVO NORDISK INC.Medication affordability and access; general diabetes prevention, 340B, monitoring FDA reform, changes and new programs. Support for obesity drug coverage and access. Treat and Reduce Obesity Act; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169) implementation. Pharmacy benefit manager reform proposals. H.R. 1, One Big Beautiful Bill Act, issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN. Issues related to corporate tax and international tax including related domestic and international tax issues for reconciliation legislation; monitor implementation of PL 119-21. General issues related to patent protections.
- 2026-04-20$60KNOVO NORDISK INC.Implementation of Inflation Reduction Act. Pharmacy Benefit Manager Reform. Health care supply chain. 340B. Treat and Reduce Obesity Act.
- 2026-04-20$60KNOVO NORDISK INC.IRA, medication affordability and access, general diabetes prevention, obesity, impacts of drug shortages, drug supply chain Treat and Reduce Obesity Act, obesity treatment Federal budget issues
- 2026-04-20$20KNOVO NORDISK INC.Issues related to obesity; Issues related to medication affordability and access
- 2026-04-17$80KNOVO NORDISK INC.Issues related to general compounding. Issues related to the clinical and overall benefit of anti-obesity medications. Issues related to insulin pricing/affordability. Issues related to general compounding. Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973). Issues related to general compounding.
- 2026-04-17$20KNOVO NORDISK INC.Issues related to compounding and counterfeit drugs. Issues related to drug pricing and implementation of the Inflation Reduction Act; coverage of anti-obesity medications; pharmacy benefit management reforms; Most Favored Nation drug pricing. Issues related to tariffs and importation of counterfeit drugs.
Congressional Momentum
buy vs. sell pressureACCUMULATINGScore 0–100: above 50 = net buying pressure, below 50 = net selling. Signal based on last 90 days.
Last 30 Days
No trades
Last 90 Days
▲100
2 buys2 total0 sells
$16K buys · $0 sells
All-Time
▲59
23 buys46 total23 sells
$649K buys · $459K sells
Cumulative Net Position (buy vol − sell vol)
+$190K
2019-0346 trades plotted2026-03
Trade Activity Timeline
Congressional buys & sells by month · last 19 months w/ activity
19/03
24/01
24/02
24/04
24/05
24/07
24/08
24/09
24/10
24/11
25/03
25/05
25/06
25/07
25/08
25/09
25/10
26/02
26/03
BuysSellsOtherHigh-volume month
Who Moved First
each row = one member · sorted by earliest disclosed trade6 buyers ·8 sellers
BuySellOtherDot size ∝ trade size · top 10 most-active traders shown
All Disclosed Trades
| Date | Member | Action | Amount | Filing Delay |
|---|---|---|---|---|
| 2026-03-13 | DRo Khanna | BUY | $1K – $15K | 25d |
| 2026-02-13 | DRo Khanna | BUY | $1K – $15K | 24d |
| 2025-10-31 | RLisa McClain | SELL | $1K – $15K | 24d |
| 2025-10-30 | RLisa McClain | SELL | $1K – $15K | 25d |
| 2025-10-30 | RLisa McClain | BUY | $1K – $15K | 25d |
| 2025-10-31 | RLisa McClain | SELL | $1K – $15K | 21d |
| 2025-10-30 | RLisa McClain | BUY | $1K – $15K | 22d |
| 2025-10-30 | RLisa McClain | SELL | $1K – $15K | 22d |
| 2025-09-11 | RLisa McClain | BUY | $1K – $15K | 42d |
| 2025-09-11 | RLisa McClain | BUY | $1K – $15K | 41d |
| 2025-08-04 | RLisa McClain | SELL | $1K – $15K | 42d |
| 2025-08-04 | RLisa McClain | SELL | $1K – $15K | 39d |
| 2024-10-29 | DValerie Hoyle | BUY | $1K – $15K | 318d |
| 2025-08-04 | RC. Franklin | BUY | $15K – $50K | 11d |
| 2025-08-04 | RC. Franklin | BUY | $1K – $15K | 11d |
| 2025-07-10 | RLisa McClain | SELL | $1K – $15K | 35d |
| 2025-06-09 | RLisa McClain | BUY | $1K – $15K | 66d |
| 2025-08-04 | RC. Franklin | BUY | $1K – $15K | 10d |
| 2025-08-04 | RC. Franklin | BUY | $15K – $50K | 10d |
| 2025-07-30 | RMichael McCaul | SELL | $50K – $100K | 14d |
| 2025-07-10 | RLisa McClain | SELL | $1K – $15K | 34d |
| 2025-06-09 | RLisa McClain | BUY | $1K – $15K | 65d |
| 2025-06-27 | RMichael McCaul | SELL | $50K – $100K | 10d |
| 2025-06-16 | RMichael McCaul | SELL | $15K – $50K | 21d |
| 2025-05-08 | RLaurel Lee | SELL | $1K – $15K | 46d |
| 2025-05-08 | RLaurel Lee | SELL | $1K – $15K | 45d |
| 2025-05-08 | RLaurel Lee | PARTIAL_SELL | $1K – $15K | 27d |
| 2025-05-08 | RLaurel Lee | BUY | $200 – $200 | 27d |
| 2025-03-20 | RByron Donalds | SELL | $1K – $15K | 25d |
| 2025-03-27 | RC. Franklin | BUY | $1K – $15K | 15d |
| 2025-03-27 | RC. Franklin | BUY | $15K – $50K | 15d |
| 2024-11-19 | RMichael McCaul | SELL | $50K – $100K | 27d |
| 2024-11-19 | RMichael McCaul | SELL | $15K – $50K | 27d |
| 2024-08-26 | RMichael McCaul | SELL | $1K – $15K | 21d |
| 2024-08-09 | RMichael McCaul | BUY | $15K – $50K | 38d |
| 2024-09-04 | RJohn James | SELL | $1K – $15K | 2d |
| 2024-07-12 | DRo Khanna | SELL | $1K – $15K | 26d |
| 2024-05-29 | RMichael McCaul | BUY | $15K – $50K | 15d |
| 2024-05-28 | RMichael McCaul | BUY | $15K – $50K | 16d |
| 2024-05-06 | RMichael McCaul | BUY | $15K – $50K | 38d |
| 2024-04-24 | RMichael McCaul | BUY | $50K – $100K | 17d |
| 2024-04-23 | RMichael McCaul | BUY | $100K – $250K | 18d |
| 2024-04-23 | RMichael McCaul | BUY | $50K – $100K | 18d |
| 2024-02-09 | DRo Khanna | SELL | $1K – $15K | 26d |
| 2024-01-19 | RTommy Tuberville | SELL | $15K – $50K | 27d |
| 2019-03-11 | RShelley Capito | SELL | $1K – $15K | 1631d |